Finalization of share buyback program in Initiator Pharma

Non Regulatory

Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 22 June 2022

Today Initiator has finalized the buyback of shares that was announced on 22 June 2022 and prolonged on 14 July 2022. In connection with the buy back, the Company has bought a total of 24,000 shares (“Treasury Shares”) at an average price of SEK 7.36.

Initiator has sold the Treasury Shares to certain members of the Board of Directors under the LTI2021-program. Each share was sold at a price of DKK 0.105 per share corresponding to par value.

The aggregate proceeds from the sale of treasury shares are DKK 2,520.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs – the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. 
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB, with email address [email protected] and phone number +46 8 121 576 90, is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Finalization of share buyback program in Initiator Pharma

Documents